Slight | Moderate | Severe | P-value | |
---|---|---|---|---|
Participants | 16 | 21 | 18 | |
Age (years) | 35.16 ± 11.81 | 39.33 ± 10.95 | 39.83 ± 11.85 | 0.43 |
Gender (M/F) | 7/9 | 8/13 | 6/12 | 0.82 |
Education | 0.96 | |||
Below 9 years, n (%) | 1 (6.25) | 2 (9.5) | 1 (5.5) | |
Up to 9 years, n (%) | 5 (31.3) | 7 (33.3) | 8 (44.4) | |
10–12 years, n (%) | 3 (18.8) | 2 (9.5) | 2 (11.1) | |
13–17 years, n (%) | 7 (43.8) | 10 (47.6) | 7 (38.9) | |
Smoking, n (%) | 2 (12.5) | 3 (14.3) | 3 (16.7) | 0.94 |
First-episode, n (%) | 10 (62.5) | 13 (61.9) | 9 (50) | 0.69 |
Baseline HAMD score | 21.94 ± 4.60 | 22.09 ± 5.04 | 22.94 ± 8.16 | 0.88 |
Baseline SCL 90 score | 200.31 ± 53.69 | 205.38 ± 70.08 | 219.56 ± 67.57 | 0.72 |
Baseline ISI score | 10.31 ± 2.94 | 16.81 ± 1.50 | 23.56 ± 1.62 | |
Current treatment | 0.78 | |||
Sertraline | 5 | 7 | 5 | |
Fluvoxamine | 6 | 4 | 4 | |
Escitalopram | 2 | 5 | 6 | |
Fluoxetine | 3 | 5 | 3 |